A Randomized, Placebo-Controlled, Double-Blinded Trial of the Safety and Efficacy of Tecovirimat for the Treatment of Human Monkeypox Virus Disease
Eligible and consented participants for the randomized arms (N=530) will be randomized 2:1 to receive either tecovirimat or placebo; participants with severe disease, significant skin conditions, participants with severe immune suppression will receive open-label tecovirimat. Participants who are pregnant or breastfeeding will receive open-label tecovirimat after discussion of the potential risks and benefits.
MoreChild to Adult
Laboratory-confirmed or presumptive HMPXV infection.
Treatment
National
Adult Infectious Disease Clinical Trials Center
Outpatient CTRC
University of Colorado Hospital
Thomas Campbell, MD
Protocol Number: 22-0797
More information available at ClinicalTrials.gov: NCT05534984
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers